These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25873774)

  • 21. Double-stranded RNA is pathogenic in Drosophila models of expanded repeat neurodegenerative diseases.
    Lawlor KT; O'Keefe LV; Samaraweera SE; van Eyk CL; McLeod CJ; Maloney CA; Dang TH; Suter CM; Richards RI
    Hum Mol Genet; 2011 Oct; 20(19):3757-68. PubMed ID: 21724553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAG-polyglutamine-repeat mutations: independence from gene context.
    Ordway JM; Cearley JA; Detloff PJ
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1083-8. PubMed ID: 10434310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases.
    Denovan-Wright EM; Davidson BL
    Gene Ther; 2006 Mar; 13(6):525-31. PubMed ID: 16237462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurodegenerative polyglutamine expansion diseases: physiopathology and therapeutic strategies].
    Ravache M; Abou-Sleymane G; Trottier Y
    Pathol Biol (Paris); 2010 Oct; 58(5):357-66. PubMed ID: 20299163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of glutamine deamidation in neurodegenerative diseases associated with triplet repeat expansions: a hypothesis.
    Hasan Q; Alluri RV; Rao P; Ahuja YR
    J Mol Neurosci; 2006; 29(1):29-33. PubMed ID: 16757807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation and gliosis in neurological diseases--clinical implications.
    Członkowska A; Kurkowska-Jastrzębska I
    J Neuroimmunol; 2011 Feb; 231(1-2):78-85. PubMed ID: 20943275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular dynamics studies of trinucleotide repeat DNA involved in neurodegenerative disorders.
    Jithesh PV; Singh P; Joshi R
    J Biomol Struct Dyn; 2001 Dec; 19(3):479-95. PubMed ID: 11790146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA triplet repeat expansion and mismatch repair.
    Iyer RR; Pluciennik A; Napierala M; Wells RD
    Annu Rev Biochem; 2015; 84():199-226. PubMed ID: 25580529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAG and CTG repeat polymorphism in exons of human genes shows distinct features at the expandable loci.
    Rozanska M; Sobczak K; Jasinska A; Napierala M; Kaczynska D; Czerny A; Koziel M; Kozlowski P; Olejniczak M; Krzyzosiak WJ
    Hum Mutat; 2007 May; 28(5):451-8. PubMed ID: 17226796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded polyglutamine stretches lead to aberrant transcriptional regulation in polyglutamine diseases.
    Shimohata T; Onodera O; Tsuji S
    Hum Cell; 2001 Mar; 14(1):17-25. PubMed ID: 11436350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program.
    Abou-Sleymane G; Chalmel F; Helmlinger D; Lardenois A; Thibault C; Weber C; Mérienne K; Mandel JL; Poch O; Devys D; Trottier Y
    Hum Mol Genet; 2006 Mar; 15(5):691-703. PubMed ID: 16434483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of neurodegeneration in polyglutamine diseases].
    Tsuji S
    Rinsho Shinkeigaku; 2003 Nov; 43(11):901-2. PubMed ID: 15152498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
    Preisinger E; Jordan BM; Kazantsev A; Housman D
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology.
    Klejbor I; Stachowiak EK; Bharali DJ; Roy I; Spodnik I; Morys J; Bergey EJ; Prasad PN; Stachowiak MK
    J Neurosci Methods; 2007 Sep; 165(2):230-43. PubMed ID: 17655935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions.
    Bates GP; Davies SW
    Mol Med Today; 1997 Nov; 3(11):508-15. PubMed ID: 9430787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A method for the incremental expansion of polyglutamine repeats in recombinant proteins.
    Robertson AL; Bottomley SP
    Methods Mol Biol; 2013; 1017():73-83. PubMed ID: 23719908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.